Objective: To study dopamine D1 and D2 receptors in the putamen and the cau
date nucleus in patients with AD and age-matched healthy controls by means
of PET. Methods: A dopamine D1 receptor antagonist ([C-11]NNC 756) and a D2
receptor antagonist ([11C]raclopride) were used as ligands. The uptake of
these ligands was calculated as a distribution volume ratio of the putamen
and the caudate nucleus to the cerebellum. Results: The mean [C-11]NNC 756
uptake in AD was reduced by 14% from the mean control. value both in the pu
tamen (p = 0.004) and the caudate nucleus (p = 0.009). There was no signifi
cant reduction in the mean [11C]raclopride uptake in either the putamen or
the caudate nucleus in AD. There was no correlation between [C-11]NNC 756 o
r [11C]raclopride uptake and Mini-Mental State Examination or motor Unified
PD Rating Scale scores in patients with AD. Conclusions: There are changes
in striatal D1 but not in D2 receptors in AD.